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Summary
Background Hilar cholangiocarcinoma (HCCA) arises
from the confluence of the common hepatic duct and
has a poor prognosis. If resectable, an extended left
(eLH) or right hemihepatectomy (eRH) is usually re-
quired to provide oncological clearance. We reviewed
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outcomes for patients with HCCA managed at our
centre.
Methods Electronic records of patients referred to our
centre for HCCA were retrospectively reviewed. The
Kaplan–Meier method was used to estimate overall
survival (OS) with the log rank test used for signifi-
cance (p< 0.05). A Cox regression was performed to
ascertain factors that may influence survival.
Results 156 HCCA patients were identified (44 re-
sected versus 112 non-resected). Resected patients
had longer OS compared to non-resected patients
(50.3 versus 9.8 months, p<0.001). Patients who un-
derwent an eLH (n=15) had significantly longer OS
at 3 years compared to eRH patients (67.7 vs. 42.1%,
respectively; p= 0.007). An eLH was an independent
predictor of survival (HR 0.43, p= 0.04). Lymph node
positivity (n=23, hazard ratio 1.72, p= 0.027) and the
presence of microvascular invasion (n= 28, hazard
ratio 1.78, p= 0.047) were independent predictors of
mortality. The frequency of lymph node positivity
and microvascular invasion did not differ between
eLH and eRH patients (p> 0.05).
Conclusion Patients undergoing an eLH for HCCA
have significantly better long-term outcomes com-
pared to those undergoing eRH, independent of other
pathological variables. The functional liver remnant
(FLR) is usually smaller following eRH, resulting in
a higher risk of post-operative liver failure. Com-
bining CT volumetry with PVE may result in better
prediction and optimisation of the FLR in the context
of eRH for HCCA.
Novel findings An extended left hemihepatectomy is
an independent predictor of survival; investigation
into the precise interaction between left- and right-
sided resections and pre- and post-embolization liver
volume is warranted.
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Introduction
Hilar cholangiocarcinoma (HCCA) is a malignant tu-
mour arising from the confluence of the common
hepatic duct into left and right branches. Patho-
logically, HCCA is known to spread longitudinally
along the bile ducts, with concomitant perineural,
microlymphatic and microvascular invasion [1, 2]. In
early HCCA, haematological spread is rare; however,
portal and pancreatic lymph node involvement is
commonly seen, with one retrospective study report-
ing lymph node metastasis in 40% of resected patients
[3].
HCCA has a poor prognosis, often due to locally
advanced disease precluding curative treatment; pa-
tients with unresectable disease are known to have
shorter survival compared to patients undergoing
resection [2, 4, 5]. HCCA is generally considered un-
resectable in the presence of bilateral intrahepatic
spread, peritoneal disease, involvement of the main
portal vein, bi-lobar vascular involvement, and/or
disease invading the contralateral hepatic artery or
portal vein [6].
Operative and non-operativemanagement of HCCA
in both the curative and palliative settings is associ-
ated with significant risks of morbidity and mortality
[1, 2]. Resectable HCCA often requires an extended
hemihepatectomy with en bloc resection of the cau-
date lobe to provide oncologic clearance of the tu-
mour, which is associated with a significant mortality
risk secondary to post-operative liver failure (PLF).
Ipsilateral portal vein embolisation (PVE) improves
operative outcomes for extended resections by in-
ducing hypertrophy in the contralateral remnant liver
pre-operatively, thereby reducing the risk of PLF [7,
8]. Biliary drainage is often necessary (as the majority
of HCCA patients become jaundiced) to palliate un-
resectable patients and to relieve biliary obstruction
in patients with potentially resectable disease [1, 7,
9]. An extended right hemihepatectomy [10] results
in a smaller functional liver remnant (FLR) compared
to an extended left hemihepatectomy (eLH), resulting
in a significantly greater risk of PLF.
The aim of our study was to analyse the outcomes
of all patients managed at our centre with HCCA dur-
ing a 10-year period. This study follows up from a pre-
vious retrospective review [2] of the management of
HCCA patients at our centre over an 8-year period
(1995–2003), which was among the first documenting
experiences in the management of HCCA in the UK
[11].
Methods
Patients
The Newcastle hepatobiliary unit is a tertiary referral
unit covering the north of England, serving a pop-
ulation of approximately 3.5 million. Patients with
cholangiocarcinoma were retrospectively identified
through hospital coding data over a 10-year period
(February 2007 to March 2017), and electronic records
were reviewed to detect patients with HCCA. Malig-
nancy was confirmed for resected patients through
pathology reports of resected specimens. In non-
resected patients HCCA was confirmed through radi-
ological imaging and serum CA 19-9 levels when ele-
vated (>1000 IU was regarded as diagnostic). In some
cases HCCA was confirmed by FNA or by a biopsy
taken at staging laparoscopy.
Investigations, staging and non-operative
management
All patients referred to our centre with a probable
diagnosis of HCCA underwent a focused multiphase
contrast-enhanced CT examination including CT an-
giography using a multidetector CT unit to fully stage
the disease. If further information was required to
confirm the diagnosis or patients were considered po-
tentially resectable, a dedicated MRI examination that
included dynamic contrast-enhanced magnetic res-
onance angiography and MRI cholangiography was
also performed. In most cases this was sufficient for
providing details on vascular involvement of hilar ves-
sels and liver volume. Tumours were radiologically
staged according to the American Joint Committee on
Cancer (AJCC) classification [12].
All jaundiced patients had percutaneous trans-
hepatic biliary drainage (PTBD). Efforts were made
not to cross the tumour where possible. For those
patients who had mildly deranged liver function tests
with a bilirubin concentration less than 70μmol/l
and who were considered resectable, patients were
admitted a few days before surgery for PTBD to allow
biliary decompression of the remnant liver. In a mi-
nority of cases, referring hospitals undertook PTBD
or endoscopic retrograde cholangiography (ERCP).
Endoscopic drainage performed at referring centres
was discouraged. In patients with unresectable HCCA
undergoing biliary drainage, self-expanding metallic
stents were placed.
In resectable patients deemed to have an inade-
quate FLR volume (generally FLR <30%, depending
on co-morbidities), PVE was performed to induce hy-
pertrophy of the remnant segments.
All patients referred to our unit for management
were discussed at the regional multi-disciplinary team
(MDT) consisting of hepatobiliary surgeons, gastroen-
terologists, oncologists, radiologists and clinical nurse
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specialists prior to commencing definitive curative or
palliative treatment.
Surgical procedures and complications
All patients with disease amenable to resection un-
derwent a staging laparoscopy to exclude occult peri-
toneal disease. The definitive procedure was either an
extended right hemihepatectomy with caudate lobec-
tomy (for Bismuth–Corlette type 1, 2 and 3a HCCA)
or an extended left hemihepatectomy with caudate
lobectomy (for Bismuth–Corlette type 3b HCCA). Pa-
tients with potentially resectable type 4 disease were
considered on a case-by-case basis to determine what
type of resection was to be performed. A Roux-en-Y
hepaticojejunostomy was used for biliary reconstruc-
tion following resection. Portal vein resections were
performed if the tumour was encasing or directly in-
volving the portal vein. Vascular continuity was re-
stored by either a primary anastomosis or graft re-
construction with bovine pericardial patches. Pan-
creaticoduodenectomy was performed concomitantly
in cases where the tumour extended into the pancre-
atic parenchyma and retro-pancreatic lymph nodes,
e.g. stations 13 and 17. All patients underwent lym-
phadenectomy at the time of resection, usually in-
volving stations 8, 9 and 12. Patients found to be
unresectable at laparotomy underwent segment 3 bil-
iary–enteric bypass if the biliary tract had already been
disconnected.
Patients experiencing post-operative bile leak (de-
fined as drain bilirubin 3 times higher than serum
bilirubin) were initially managed conservatively; the
presence of fever (or any symptoms or signs of infec-
tion) resulted in the initiation of antibiotic therapy,
tailored to bile cultures taken peri-operatively. PTBD
was performed for bile leaks persisting after post-op-
erative day 10 where obstruction was demonstrated
on magnetic resonance cholangiography. Symp-
tomatic bilomas were drained percutaneously under
ultrasound guidance.
Complications were graded according to the
Clavien–Dindo classification [13].
Chemotherapy
In line with existing evidence, we did not routinely
offer adjuvant chemotherapy for patients who had
undergone resection with curative intent. All pa-
tients with unresectable disease were offered pallia-
tive chemotherapy (typically gemcitabine/cisplatin)
provided adequate biliary drainage (defined as serum
bilirubin ≤27µmol/L [≤1.58mg/dL]) had been achieved
and patient performance status allowed. All patients
developing disease recurrence following surgery are
considered for palliative chemotherapy.
Statistical analysis
Statistical analysis was performed using SPSS ver-
sion 22 (IBM Corp, Armonk, NY, USA). Overall sur-
vival (OS) and disease-free survival (DFS) were esti-
mated using the Kaplan–Meier method, with com-
parisons made using the log-rank test. Contin-
uous variables were compared using the t-test or
Mann–Whitney U test. CA 19-9 elevated above the
median value for the population was defined as high.
Variables found to be statistically significant were
included in a multivariate analysis using the Cox pro-
portional hazards model. All statistical tests were two-
tailed, and a p-value <0.05 was considered significant.
For comparison of survival between eLH and eRH,
analysis was based on the resection intended based
on pre-operative imaging and multi-disciplinary team
discussion.
Results
A total of 156 patients with confirmed HCCA were
managed at our centre. The male to female ratio
was 1:1 and the median age at presentation for all
HCCA patients was 68 years (42–91). For resected
patients, the median age was 61 years (42–71), com-
pared with 72 years (42–91) for non-resected patients
(p< 0.0001). There was no difference in median age
when comparing patients who underwent eLH with
patients who underwent eRH (60 vs. 61, p> 0.05).
A total of 115 patients (73.7%) presented with jaun-
dice, with the remainder presenting with right upper
quadrant pain, weight loss, deranged liver function
tests or incidentally on CT imaging. Following staging
laparoscopy, 14 patients were excluded for resection
due to peritoneal disease. A laparotomy for resection
was performed in 44 patients (Table 1); 112 patients
were deemed to have unresectable HCCA.
Investigations
All resected patients had a CT scan pre-operatively
and 28 (63.6%) patients underwent MR imaging as
well; amongst the non-resected patients, 108 (96.4%)
underwent CT scanning and 37 (33.0%) underwent
MR imaging. The median CA 19-9 at the time of diag-
nosis in the resected group was 126 iU/mL compared
to 647 iU/mL in the non-resected group (p< 0.0001).
Median CA 19-9 at diagnosis did not differ when com-
paring patients undergoing eLH with patients under-
going eRH (103 vs. 147, p>0.05).
Table 1 Surgical procedures
Procedure N
Extended right hemihepatectomy 27
Extended left hemihepatectomy 14
Extrahepatic bile duct resection 1
Failed trial dissection (segment 3 biliary-enteric bypass) 2
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Pre-operative biliary drainage, post-operative biliary
drainage and PVE
In the resected group all 44 patients underwent pre-
operative biliary drainage, of whom 5 patients (11.4%)
were drained via ERCP and 39 patients (88.6%) were
drained via PTBD. Amongst non-resected patients
a total of 167 PTBDs were performed; the median
number of PTBDs per patient was 1 (0–7), and
10 PTBDs failed (6.0%). 22 non-resected patients
(19.6%) underwent ERCP of which 4 failed.
Post-resection, 11 patients (25%) required drainage
via PTBDs for post-operative bile leaks; a total of
22 PTBDs were performed, of which 3 failed.
A total of 11 patients (25%) underwent PVE pre-
operatively to increase the FLR, of which all were of
the right portal vein in patients undergoing an eRH.
Surgical procedures and complications
Amongst the 44 patients who underwent resection
with curative intent (Table 1), 2 patients (4.5%) were
found to have unresectable HCCA at laparotomy, and
surgical bypass was performed. A total of 15 patients
underwent eLH and 29 patients underwent eRH. En
bloc pancreatectomy was necessary in 7 patients
(15.9%), of which 5 were pylorus-preserving pancre-
aticoduodenectomies and 2 were total pancreato-
splenectomies. Of the 7 patients requiring pancreatic
resection, 1 patient was in the eLH group and 6 pa-
tients were in the eRH group. Portal vein resection
was performed in 11 patients (25.0%), with 1 patient
requiring a graft reconstruction with an equine patch.
Post-operative histopathology demonstrated vascular
invasion in 4 patients (36.3%) who underwent portal
vein resection. Among the patients undergoing portal
vein resection, 4 patients were in the eLH compared
to 7 patients in the eRH group.
Post-operative complications are summarised in
Table 2. Post-operatively, 35 patients (79.5%) expe-
rienced complications, of whom 23 patients (52.3%)
demonstrated complications ≥grade 3a. The number
of patients experiencing major post-operative compli-
cations (≥grade 3a) was no different when comparing
patients who underwent eLH with patients who un-
derwent eRH (7 vs. 16, p>0.05).
Resection, chemotherapy and survival
In resected patients the 1-, 3- and 5-year OS was
92.0%, 56.0% and 38.0%, respectively, with a median
OS of 50.3 months (±32.2), with a 90-day all-cause
mortality rate of 11.4% (n= 5). In patients who un-
derwent concomitant pancreatic resection (n= 7), the
90-day mortality rate was 14.3% (n=1). This was
significantly higher than median OS in non-resected
patients (9.8 months± 3.8) with 1-, 3- and 5-year OS of
41.7%, 6.5% and 1.6%, respectively (p< 0.001; Fig. 1).
Table 2 Post-operative complications
Complication n
Grade I 6
Wound infection 2
Wound seroma 1
Bile leak 3
Grade II 10
Pneumonia 1
Bile leak 3
Chyle leak 1
Portal vein thrombosis 1
Biliary sepsis 3
Non-biliary sepsis 1
Grade IIIa 9
Peri-hepatic collection 4
Pleural effusion 2
Pleuro-peritoneal fistula 1
Empyema 1
Bile leak 1
Grade IIIb 2
Bowel infarction 1
Hepatic artery pseudoaneurysm 1
Grade IVa 8
Transient liver failure 4
Acute kidney injury 4
Grade IVb 3
Sepsis 2
Intra-abdominal haemorrhage 1
Grade V/post-operative death 5
Sepsis 1
Intracranial haemorrhage 1
Hepatic artery thrombosis 1
Multi-organ dysfunction syndrome 2
Total 43
Patients undergoing eLH demonstrated signifi-
cantly longer OS compared to patients undergoing
eRH (p= 0.007; Fig. 2). The 1-, 3- and 5-year OS in
patients undergoing eLH for HCCA was 100%, 67.7%
and 58%, respectively. In patients undergoing eRH
for HCCA, the 1-, 3- and 5-year OS was 87.8%, 42.1%
and 0%, respectively. DFS was significantly longer in
patients undergoing eLH (p= 0.006). The 1-, 3- and
5-year DFS in the eLH group was 100%, 60.6% and
51.9%, respectively. In the eRH group the 1-, 3- and
5-year DFS was 66%, 21% and 0%.
A total of 21 patients (47.7%) demonstrated dis-
ease recurrence post-operatively. The patients with
recurrence receiving chemotherapy demonstrated
a longer median survival compared to patients with
recurrence who were not offered chemotherapy (39.3
versus 26.7 months); however, this did not reach sta-
tistical significance (p=0.813). Amongst non-resected
patients, those who received palliative chemotherapy
(n= 24) had a much longer median OS compared to
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Fig. 1 Overall survival
(OS) in resected patients
compared with non-resect-
ed patients. Median OS in
resected patients was 50.3
months versus 9.8 months
in non-resected patients
(p< 0.0001)
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non-resected patients who did not receive chemother-
apy (15.5± 4.3 versus 6.4± 1.6 months, p< 0.0001).
Prognostic factors for OS
In univariate analysis (Table 3), significant predic-
tors of shorter OS in the resected group were eRH
(p= 0.006), microvascular invasion (p=0.025), lymph
node positivity (p=0.013). Resection margin (R0
n= 11), en bloc caudate resection (n=36), en bloc
pancreatectomy (n= 7), perineural invasion (n= 33),
portal vein embolisation (n=11) and portal vein re-
section (n=11) did not impact on OS in univariate
analysis. In multivariate analysis (Table 4), indepen-
dent predictors of survival were eLH (HR 0.41 95%
CI 0.23–0.76; p= 0.004), the absence of microvascular
invasion on post-operative pathological examination
(HR 0.56 95% CI 0.31–0.99; p= 0.047) and negative
lymph nodes (HR 0.58 95% CI 0.36–0.94; p= 0.027).
Discussion
Resection is the only treatment option offering long-
term survival to patients with HCCA. In our series, an
aggressive surgical approach conferred a significant
survival benefit compared to those who were not re-
sected. Among resectable patients, an extended left
hemihepatectomy was an independent predictor of
survival. This associated survival benefit is likely to
be related to a larger FLR following eLH, resulting in
a reduced risk of PLF compared to right-sided resec-
tions. Additionally, from an anatomical perspective,
left-sided lesions may be more amenable to curative
resection. The left hepatic duct is longer than the
right, and divides into segmental branches later in
its course compared to the right hepatic duct; con-
sequently, left-sided lesions may be easier to access at
resection. This is further supported by our observa-
tion that DFS is significantly longer in patients under-
going eLH.
Pre-operative PVE of the ipsilateral lobe and con-
tralateral PTBD are strategies known to increase the
FLR [1, 7, 9, 14]. CT volumetry may help stratify pa-
tients into high- or low-risk categories for PLF, guiding
pre-operative optimisation of patients with potentially
resectable disease by identifying patients with poten-
tially resectable disease who may benefit from PVE.
Currently, no standardised pre-operative pathway ex-
ists for patients with potentially resectable HCCA; de-
velopment and subsequent audit of a HCCA resection
pathway may improve outcomes for such patients.
The need for portal vein resection and, when re-
quired, simultaneous en bloc pancreaticoduodenec-
tomy did not significantly affect OS in our series.
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Fig. 2 Overall survival
(OS) by type of resec-
tion. OS at 3 years in pa-
tients who underwent an
extended left hemihepa-
tectomy was 67.7% com-
pared to 42.1% in pa-
tients who underwent an
extended right hemihepate-
ctomy (p= 0.007)
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Resection
In a recent series that included a UK centre [15],
combined pancreaticoduodenectomy (performed in
12 patients) was found to be a predictor of a higher
rate of post-operative complications; however, no
comment was made on its impact on OS. In our se-
ries, an R1 resection margin was not associated with
shorter OS compared to an R0 margin, which has also
been described by others in the UK [11]. Nevertheless
this is not consistent across the board as microscopic
tumour involvement at the resection margin can also
be associated with worse rates of survival [5, 16–18].
As in other tumour types, this may be explained by
discrepancies in histological reporting [19–21].
All patients in our series underwent portal lym-
phadenectomy, with clearance of the retro-pancreatic
nodes if a pancreatectomy was also performed; lymph
node involvement was associated with mortality in
our series; therefore, en bloc resection may improve
the efficacy of resection. The degree to which lym-
phadenectomy should be performed has not been
standardised across centres. Extended lymphadenec-
tomy is unlikely to confer any significant survival
benefit [4]. A UK series of patients undergoing re-
section for HCCA [11] stated that all patients (n= 44)
routinely underwent coeliac lymphadenectomy, of
which 17 patients also underwent clearance of the
para-aortic lymph nodes. The efficacy of performing
such an extended lymphadenectomy is questionable,
as suggested by others [2–4, 18, 22]. For example,
patients having just a regional lymphadenectomy of
the hepato-duodenal ligament have similar or supe-
rior 5-year survival rates compared to those having
a more radical lymphanectomy, with the latter also
having higher rates ofmorbidity. However, a study [23]
investigating the efficacy of extended lymphadenec-
tomy to the coeliac and para-aortic lymph nodes
found that 5-year survival in patients with para-aortic
lymph node metastasis was 15% and that extended
lymphadenectomy did benefit some patients. How-
ever, another study [22] reported a 2-year survival rate
of 0% in resected patients with lymph node metastasis
beyond the hepato-duodenal ligament and it is there-
fore not surprising this study did not recommend
extended lympadenectomy as routine.
Resection of an involved portal vein was carried out
in 11 patients in our series. This has been shown to
provide better oncological clearance [24], with 1- and
3-year survival rates of 87% and 70%, respectively [25].
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Table 3 Univariate analysis of clinico-pathological vari-
ables that may influence OS in patients with HCCA under-
going resection
Variable N HR (95% CI) p-value
Type of resection
eLH vs. eRH 15 vs. 29 0.46 (0.26–0.80) 0.006
High CA 19-9 (>126iU/mL)
Low vs. high 19 vs. 22 0.83 (0.53–1.32) 0.440
PVE
No PVE vs. PVE 33 vs. 11 0.87 (0.52–1.46) 0.600
T-stage
T1/T2 vs. T3/T4 20 vs. 21 0.70 (0.44–1.12) 0.137
Microvascular invasion
Negative vs. positive 16 vs. 28 0.53 (0.31–0.92) 0.025
Perineural invasion
Negative vs. positive 11 vs. 33 0.64 (0.33–1.26) 0.200
Resection margin
R0 vs. R1 11 vs. 29 0.81 (0.50–1.31) 0.385
Lymph node involvement
No vs. yes 21 vs. 23 0.55 (0.35–0.88) 0.013
Portal vein resection
No vs. yes 33 vs. 11 0.90 (0.54–1.53) 0.703
En bloc pancreatic resection
No vs. yes 37 vs. 7 0.75 (0.44–1.27) 0.282
Clavien–Dindo grade of complication ≥grade 3a
Yes vs. no 19 vs. 25 – 0.406
HCCA hilar cholangiocarcinoma, OS overall survival
Table 4 Multivariate analysis of clinico-pathological vari-
ables
Variable HR 95% CI p-value
Resection
eLH vs. eRH 0.41 0.23–0.76 0.004
Microvascular invasion
No vs. yes 0.56 0.31–0.99 0.047
Lymph node involvement
No vs. yes 0.58 0.36–0.94 0.027
Although portal vein resection has become somewhat
routine in order to achieve oncological clearance,
there is some evidence that portal vein resection may
not provide any long-term benefit to patients with
HCCA, due to increased morbidity [18, 26]. Studies
have reported similar survival rates for patients who
underwent portal vein resection compared to patients
in whom portal vein resection was not necessary [16,
18, 27]. A prospective study investigating the im-
pact of portal vein resection on long-term outcome
may be beneficial in establishing standard practice.
In our series, no patients underwent arterial resec-
tion. There have been no major prospective studies
investigating the efficacy of hepatic artery resection
and reconstruction; however, anecdotal reports have
suggested that arterial resection may be beneficial in
selected patients [28–30] with arterial encasement/
involvement, although morbidity and mortality may
be significantly higher. A Japanese study [31] evalu-
ated outcomes of HCCA patients undergoing hepatic
arterial resection and reported an operative mortality
rate of 33% and a 3-year survival rate of 0%. This
finding confirms that arterial resection is question-
able. Arterial resection results in prolonged warm
ischaemia of the liver parenchyma, which may con-
tribute to the higher mortality observed in such pa-
tients. However, Nagino et al. reported a series of
50 patients with HCCA who underwent simultaneous
portal vein and hepatic artery resection and recon-
struction, with a 5-year survival rate of 30.6% [30].
Despite such a high 5-year survival rate, such patients
experienced a lower survival compared to patients
who did not require vascular resection. Therefore,
arterial resection and reconstruction performed in
high-volume centres may be more justifiable.
Pre-operative biliary drainage (PTBD) has become
an essential part of the preparation of patients for re-
section. Although establishing adequate drainage can
be associated with complications or mortality [9, 15],
abandoning the practice would be unwise. Our prac-
tice is to ensure that the remaining lobe is well drained
and the serum bilirubin is <70µmol/L (<4.09mg/dL).
Standard practice in our centre for patients requiring
pre-operative biliary drainage is to perform a PTBD
rather than ERCP, as previous studies have demon-
strated that ERCP is associated with a significantly
greater risk of complications compared to PTBD [32],
despite ERCP being more physiological.
Surgical resection of an obstructed liver is asso-
ciated with poor outcomes due to coagulopathy, in-
creased risk of cholangitis/biliary sepsis and increased
risk of PLF secondary to liver atrophy [7]. Pre-op-
erative biliary drainage of the FLR has been shown
to improve outcome where the FLR is less than 30%
[33]. A retrospective study [33] found that pre-op-
erative PTBD resulting in an FLR >30% was associ-
ated with fewer post-operative complications and bet-
ter survival compared to patients with a FLR <30%
(which was found to be a strong predictor of mor-
bidity and mortality). Patients with a FLR <30% who
underwent drainage experienced fewer complications
and a higher survival rate.
However, a significant proportion demonstrated
disease progression requiring a change in regimen.
Studies investigating second-line chemotherapy reg-
imens in advanced biliary tract malignancies are
lacking but trials are currently ongoing (e.g. ABC-
06 trial investigating oxaliplatin and a modified de
Gramont for patients previously treated with gemc-
itabine and cisplatin). Stereotactic body radiother-
apy (SBRT) is another treatment modality that may
offer longer survival to patients with unresectable
HCCA. An American series retrospectively reviewed
patients with cholangiocarcinoma who were treated
with SBRT, demonstrating a median OS 17.0 months
[34]. No randomised controlled trials investigating
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SBRT have been published; however, the ABC-07 trial
is ongoing to investigate the feasibility of systemic
chemotherapy (gemcitabine and cisplatin) plus SBRT.
The role for adjuvant and neoadjuvant chemother-
apy in resectable HCCA is yet to be established,
with clinical trials ongoing and yet to be reported.
The BILCAP trial [35], investigating the efficacy of
capecitabine for adjuvant chemotherapy in patients
with cholangiocarcinoma, suggests that adjuvant
chemotherapy extends median OS and should be
routine practice. In our series, the longer OS for pa-
tients with recurrence who received chemotherapy
compared to patients with recurrence who were not
offered chemotherapy was not statistically significant;
however, we continue to offer palliative chemother-
apy to this group based on the evidence from the
ABC-02 trial.
Our series is one of the few studies investigating the
management of HCCA in a UK centre. We continue
to advocate an aggressive surgical approach to treat-
ing patients with HCCA, as this offers the only hope
of long-term survival. In our series, a left-sided resec-
tion was an independent predictor of survival. This
is likely to be related to an increased risk of PLF (and
further subsequent morbidity) following eRH due to
a smaller FLR. Combining CT volumetry with PVE
may result in better prediction and optimisation of
the FLR in the context of eRH for HCCA, with a po-
tential role for a standardised pre-operative HCCA re-
section pathway. Future prospective studies into the
use of vascular resection and reconstruction, the tim-
ing of chemotherapy and the efficacy of SBRT would
provide initial insight into establishing standard prac-
tices in the management of HCCA.
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